Seventh Edition, International Comparative Legal Guides

Download PDF

Norton Rose Fulbright lawyers Roger Kuan, Ebony Christian, Apurv Gaurav, Dr. Nathanael Green, Jason Novak and Sophia Poirier contributed several chapters to Digital Health 2026 International Comparative Legal Guide, published by ICLG, which is a leading global platform for legal reference, analysis and news. Roger also served as a contributing editor for the publication.

Chapter 1 | Introduction

Authors: Roger Kuan, Norton Rose Fulbright and David Wallace, Johnson & Johnson

The rapid convergence of digital technologies with healthcare over the past decade has fundamentally reshaped how healthcare is developed, delivered, reimbursed and regulated. What began as digitization of records and workflows has, by 2026, evolved into artificial intelligence (AI)-enabled, data-native healthcare systems that increasingly operate in real time and at population scale.

Digital health now represents a shift away from episodic, provider-centric care toward continuous, patient-centered, data-driven care models. These models integrate clinical data, real-world evidence, genomics, imaging, wearable and sensor data and patient-reported outcomes to support individualized prevention, diagnosis, treatment and monitoring. The modern digital health paradigm emphasizes personalization, interoperability, automation and outcomes-based care, supported by cloud infrastructure and advanced analytics.

A defining change in 2026 is the transition of AI from experimental deployment to embedded clinical and operational infrastructure forcing digital health companies to treat AI models as regulated product components subject to lifecycle controls, auditability and post-market monitoring. AI is now routinely used for clinical decision support, workflow automation, triage, imaging interpretation, drug development and population health management, with regulators and payors increasingly demanding transparency, validation and postmarket performance monitoring.

At the same time, governments and regulators have moved aggressively to address trust, safety and accountability. Regulatory frameworks for software as a medical device (SaMD), AI/machine learning (ML)-enabled medical devices, digital therapeutics (DTx) and real-world data have matured, reducing uncertainty while raising the bar for evidence generation, cybersecurity, data governance and lifecycle compliance.

From a market perspective, digital health growth has continued, but with a clear shift from speculative adoption to enterprise-scale procurement, platform consolidation and reimbursement-aligned deployment. Health systems and life sciences companies now prioritize solutions that demonstrate measurable clinical outcomes, cost reduction and workflow efficiency, rather than standalone point solutions. For digital health companies, the post-pandemic market has shifted decisively from rapid pilot adoption to disciplined, enterprise-scale procurement. Buyers now prioritize regulatory readiness, reimbursement alignment, cybersecurity posture and demonstrable outcomes over feature velocity or novelty. A November 2020 report by Precedence Research published on GlobeNewsWire indicates that the global digital health market is poised to grow at a compound annual growth rate of around 27.9 percent over the next seven years to reach approximately US$833.44 billion by 2027.

Chapter 8 | The Bio-Industrial Technology Stack: A new framework for national sovereignty in the century of biology

Authors: Jason Novak, Dr. Nathanael Green and Sophia Poirier Norton Rose Fulbright and Dr. Milad Alucozai, Revalia Bio

We are standing at the edge of a new industrial era. If the last century was defined by the physics of the atom and the logic of the digital bit, this one will be defined by the engineering of the cell. Biotechnology is moving past its history as a field of artisanal discovery that relied on luck and manual labor. It is maturing into a predictable and scalable industrial force. We have arrived here because of a convergence that makes this moment distinct from the biotech sector of the last 25 years: the collision of massive computing power, generative AI and high throughput automation is finally allowing us to treat biology as a rigorous engineering discipline rather than an observational science.

This is no longer just about medicine or science; it is about a new fundamental economic architecture and the ability to define, scale and secure the products of the future across various industries. From the food we grow to the essential medicines we stockpile, the ability to engineer and scale biology is becoming the central axis of global economic security.

This transition from science project to strategic infrastructure development fundamentally alters the geopolitical map. For decades, the United States (US) held a monopoly on biotechnology as a whole and effectively wrote the operating manual for modern life sciences. But as biotechnology development has evolved from pure research to complex engineering, that monopoly has fractured. We are now navigating a multipolar world where leadership is determined not just by who can discover a molecule, but by who can build it, scale it and secure it, i.e. who can lead each layer of the ‘Bio-Industrial Technology Stack’ (BITS) explored in this chapter.

Chapter 22 | The geopolitical tipping point: Forecasting global Bio-Industrial Technology Stack (BITS) dominance through 2050

Authors: Jason Novak, Dr. Nathanael Green and Ebony Christian Norton Rose Fulbright and Dr. Milad Alucozai, Revalia Bio

Building upon the Bio Industrial Technology Stack (BITS) framework, this chapter forecasts how the interlocking engines of the Code, Tools and Factory layers will be contested by the United States, European Union, India and China through 2050. To lead the conversation, we must move beyond the standard call for “more funding” and frame this as a structural and philosophical shift in how a nation secures its future. As a refresher, we define the layers for the BITS framework as follows:

Layer 1: The Design Engine (The Code)

This represents the upstream architecture where biology is transformed into a more rigorous engineering discipline.

Layer 2: The Validation Engine (The Tools)

This engine serves as the high-fidelity filter of the stack, bridging the gap between digital design and physical truth through various tools, including analytical software and instrumentation.

Layer 3: The Execution Engine (The Factory)

This constitutes the hard infrastructure of mass production and sovereign supply chains.

Chapter 23 | USA

Authors: Roger Kuan, Jason Novak and Apurv Gaurav Norton Rose Fulbright

In the United States, Digital health is a technology sector that is a convergence of high technology with healthcare. The result is a highly personalized healthcare system that is focused on data-driven healthcare solutions, individualized delivery of therapeutics and treatments to patients powered by information technologies that enable seamless integration and communication between patients, providers, payors, researchers and health information depositories.

The key emerging digital health technologies in the US are:

  • Personalized/Precision medicine
  • Clinical decision support tools
  • Remote patient monitoring and delivery of care
  • Big data analytics
  • Artificial intelligence/Machine learning (AI/ML)
  • Robot-assisted surgery
  • Digital hospital
  • Digital therapeutics
  • Generative AI

Contact